Artiva Biotherapeutics (ARTV) Projected to Announce Quarterly Earnings on Wednesday

Artiva Biotherapeutics (NASDAQ:ARTV) is expected to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect Artiva Biotherapeutics to post earnings of ($0.54) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:00 PM ET.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.63). On average, analysts expect Artiva Biotherapeutics to post ($2.71) EPS for the current fiscal year and ($1.96) EPS for the next fiscal year.

Artiva Biotherapeutics Stock Up 1.0%

Shares of ARTV opened at $4.24 on Wednesday. The company has a market capitalization of $207.29 million, a price-to-earnings ratio of -1.28 and a beta of 2.67. Artiva Biotherapeutics has a 52-week low of $2.96 and a 52-week high of $14.53. The stock has a 50 day moving average price of $7.83 and a 200 day moving average price of $7.96.

Insider Activity at Artiva Biotherapeutics

In other news, insider Christopher Horan sold 10,340 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $6.84, for a total transaction of $70,725.60. Following the sale, the insider owned 312,744 shares of the company’s stock, valued at $2,139,168.96. The trade was a 3.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Fred Aslan sold 61,696 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $422,000.64. Following the completion of the sale, the chief executive officer owned 1,543,069 shares in the company, valued at approximately $10,554,591.96. This represents a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 137,048 shares of company stock valued at $1,086,167. 1.80% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ARTV shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Monday, October 19th. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price objective on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd. Needham & Company LLC cut Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 27th. Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, TD Cowen cut Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 27th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $24.80.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.